The BioFire® RP2.1 Panel Did Not Identify Concurrent Respiratory Virus Infection in Adults with Variable SARS-CoV-2 Disease Severity and Infection Duration

Table 2

COVID-19 severity and concurrent respiratory infections.

			BioFire® testing
Disease severity	# of individuals		SARS-CoV-2 (+)		Other respiratory pathogens (+)
	Cohort 1 (n = 122)	Cohort 2^1 (n = 23)	Cohort 1	Cohort 2	Cohort 1	Cohort 2
Asymptomatic	6 (4.9%)	9 (39.1%)	3 (50.0%)	8 (88.9%)	0 (0%)	0 (0%)
Mild	48 (39.3%)	7 (30.4%)	15 (31.3%)	7 (100%)	0 (0%)	1 (14.3%)
Moderate	33 (27.0%)	6 (26.1%)	22 (66.7%)	6 (100%)	0 (0%)	0 (0%)
Severe	35 (28.7%)	1 (4.3%)	27 (77.1%)	1 (100%)	0 (0%)	0 (0%)

¹Five individuals declined to complete the symptom survey.